Bio-Techne Corp
TECH50.300USD
+0.060+0.12%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
7.94BMarktkapitalisierung
50.24KGV TTM
mehr Informationen über Bio-Techne Corp Unternehmen
Bio-Techne Corporation is a global life sciences company providing tools and bioactive reagents for the research and clinical diagnostic communities. The Company's products assist scientific investigations into biological processes and the nature and progress of specific diseases. The Company, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex Bioreactors. Its segments include Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, and tissue biopsy analysis.
Unternehmensinformationen
Unternehmens-codeTECH
Name des UnternehmensBio-Techne Corp
IPO-datumFeb 09, 1989
Gegründet am1981
CEOMr. Kim Kelderman
Anzahl der mitarbeiter3100
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 09
Addresse614 Mckinley Pl N E
StadtMINNEAPOLIS
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl55413
Telefon16123798854
Websitehttps://www.bio-techne.com/
Unternehmens-codeTECH
IPO-datumFeb 09, 1989
Gegründet am1981
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. John L. Higgins
Mr. John L. Higgins
Independent Director
Independent Director
48.20K
+3.13%
Mr. Robert V. (Bob) Baumgartner, CPA
Mr. Robert V. (Bob) Baumgartner, CPA
Independent Chairman of the Board
Independent Chairman of the Board
44.86K
+3.37%
Dr. Roeland Nusse, Ph.D.
Dr. Roeland Nusse, Ph.D.
Independent Director
Independent Director
44.56K
+3.39%
Mr. Kim Kelderman
Mr. Kim Kelderman
President, Chief Executive Officer, Chief Operating Officer, Director
President, Chief Executive Officer, Chief Operating Officer, Director
37.51K
--
Dr. Joseph D. (Joe) Keegan, Ph.D.
Dr. Joseph D. (Joe) Keegan, Ph.D.
Independent Director
Independent Director
13.77K
+11.88%
Dr. Rupert J. Vessey, Ph.D.
Dr. Rupert J. Vessey, Ph.D.
Independent Director
Independent Director
9.35K
+18.54%
Ms. Julie L. Bushman
Ms. Julie L. Bushman
Independent Director
Independent Director
7.13K
+25.77%
Mr. Shane Bohnen
Mr. Shane Bohnen
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
3.19K
+90.01%
Dr. Matthew F. Mcmanus
Dr. Matthew F. Mcmanus
President - Diagnostics and Genomics Segment
President - Diagnostics and Genomics Segment
2.98K
--
Dr. Judith V. Klimovsky, M.D.
Dr. Judith V. Klimovsky, M.D.
Independent Director
Independent Director
2.14K
+215.00%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. John L. Higgins
Mr. John L. Higgins
Independent Director
Independent Director
48.20K
+3.13%
Mr. Robert V. (Bob) Baumgartner, CPA
Mr. Robert V. (Bob) Baumgartner, CPA
Independent Chairman of the Board
Independent Chairman of the Board
44.86K
+3.37%
Dr. Roeland Nusse, Ph.D.
Dr. Roeland Nusse, Ph.D.
Independent Director
Independent Director
44.56K
+3.39%
Mr. Kim Kelderman
Mr. Kim Kelderman
President, Chief Executive Officer, Chief Operating Officer, Director
President, Chief Executive Officer, Chief Operating Officer, Director
37.51K
--
Dr. Joseph D. (Joe) Keegan, Ph.D.
Dr. Joseph D. (Joe) Keegan, Ph.D.
Independent Director
Independent Director
13.77K
+11.88%
Dr. Rupert J. Vessey, Ph.D.
Dr. Rupert J. Vessey, Ph.D.
Independent Director
Independent Director
9.35K
+18.54%
Umsatzaufteilung
Währung: USDUpdate-Zeit: Sun, Apr 6
Währung: USDUpdate-Zeit: Sun, Apr 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Consumables
230.72M
77.67%
Instruments
30.87M
10.39%
Service
27.35M
9.21%
Royalty
8.10M
2.73%
Nach RegionUSD
Name
Umsatz
Anteil
United States
159.91M
53.83%
EMEA, excluding U.K
70.39M
23.70%
Greater China
24.75M
8.33%
APAC, excluding Greater China
19.01M
6.40%
United Kingdom
13.24M
4.46%
Rest of World
9.73M
3.27%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Consumables
230.72M
77.67%
Instruments
30.87M
10.39%
Service
27.35M
9.21%
Royalty
8.10M
2.73%
Aktionäre
Update-Zeit: Fri, Feb 21
Update-Zeit: Fri, Feb 21
Aktionärsstatistik
Art
Aktionärsstatistik
Aktionäre
Anteil
The Vanguard Group, Inc.
11.72%
T. Rowe Price Associates, Inc.
6.60%
BlackRock Institutional Trust Company, N.A.
5.85%
State Street Global Advisors (US)
4.09%
Baron Capital Management, Inc.
2.62%
Other
69.12%
Aktionärsstatistik
Aktionäre
Anteil
The Vanguard Group, Inc.
11.72%
T. Rowe Price Associates, Inc.
6.60%
BlackRock Institutional Trust Company, N.A.
5.85%
State Street Global Advisors (US)
4.09%
Baron Capital Management, Inc.
2.62%
Other
69.12%
Art
Aktionäre
Anteil
Investment Advisor/Hedge Fund
47.40%
Investment Advisor
44.16%
Hedge Fund
2.25%
Bank and Trust
2.16%
Pension Fund
1.88%
Research Firm
1.54%
Sovereign Wealth Fund
1.27%
Individual Investor
1.04%
Insurance Company
0.23%
Institutionelle Beteiligung
Update-Zeit: Mon, Jan 20
Update-Zeit: Mon, Jan 20
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q1
1193
162.20M
102.60%
-2.87M
2024Q4
1233
162.21M
102.61%
-6.39M
2024Q3
1205
159.40M
100.49%
-10.21M
2024Q2
1207
160.52M
101.86%
-12.24M
2024Q1
1216
162.56M
103.40%
-7.57M
2023Q4
1229
159.70M
100.98%
-3.97M
2023Q3
1217
156.41M
98.84%
-7.93M
2023Q2
1213
155.36M
98.68%
-4.04M
2023Q1
1206
153.08M
97.33%
-5.18M
2022Q4
1190
153.16M
97.57%
-6.72M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
18.52M
11.72%
+275.81K
+1.51%
Dec 31, 2024
T. Rowe Price Associates, Inc.
10.43M
6.6%
+1.23M
+13.34%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
9.25M
5.85%
+4.60K
+0.05%
Dec 31, 2024
State Street Global Advisors (US)
6.47M
4.09%
+76.69K
+1.20%
Dec 31, 2024
Baron Capital Management, Inc.
4.14M
2.62%
-308.56K
-6.94%
Dec 31, 2024
Geode Capital Management, L.L.C.
4.00M
2.53%
+98.66K
+2.53%
Dec 31, 2024
Neuberger Berman, LLC
3.58M
2.27%
+65.69K
+1.87%
Dec 31, 2024
D. F. Dent & Company, Inc.
3.20M
2.03%
-97.30K
-2.95%
Dec 31, 2024
Atlanta Capital Management Company, L.L.C.
2.95M
1.87%
-40.17K
-1.34%
Dec 31, 2024
Mairs and Power, Inc.
2.82M
1.78%
-24.98K
-0.88%
Dec 31, 2024
Mehr Anzeigen
Verbundene ETFs
Update-Zeit: Sun, Apr 6
Update-Zeit: Sun, Apr 6
Name
Anteil
Global X Genomics & Biotechnology ETF
4.16%
Invesco Biotechnology & Genome ETF
2.26%
Tema Monopolies and Oligopolies ETF
1.9%
VanEck Biotech ETF
1.79%
Hilton Small-MidCap Opportunity ETF
1.77%
Thrivent Small-Mid Cap ESG ETF
1.75%
iShares Health Innovation Active ETF
1.72%
Neuberger Berman Small-Mid Cap ETF
1.49%
Invesco S&P 500 Equal Weight Health Care ETF
1.27%
American Century Mid Cap Growth Impact ETF
0.98%
Mehr Anzeigen
Global X Genomics & Biotechnology ETF
Anteil4.16%
Invesco Biotechnology & Genome ETF
Anteil2.26%
Tema Monopolies and Oligopolies ETF
Anteil1.9%
VanEck Biotech ETF
Anteil1.79%
Hilton Small-MidCap Opportunity ETF
Anteil1.77%
Thrivent Small-Mid Cap ESG ETF
Anteil1.75%
iShares Health Innovation Active ETF
Anteil1.72%
Neuberger Berman Small-Mid Cap ETF
Anteil1.49%
Invesco S&P 500 Equal Weight Health Care ETF
Anteil1.27%
American Century Mid Cap Growth Impact ETF
Anteil0.98%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
249.41M
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Feb 05, 2025
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Feb 28, 2025 going ex on Feb 14, 2025
Feb 17, 2025
Feb 28, 2025
Feb 14, 2025
Oct 30, 2024
TECH.NB Final Cash Dividend of gross USD 0.08 paid on Nov 22, 2024 going ex on Nov 08, 2024
Nov 11, 2024
Nov 22, 2024
Nov 08, 2024
Aug 07, 2024
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Aug 30, 2024 going ex on Aug 19, 2024
Aug 19, 2024
Aug 30, 2024
Aug 19, 2024
May 01, 2024
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on May 24, 2024 going ex on May 10, 2024
May 13, 2024
May 24, 2024
May 10, 2024
Feb 01, 2024
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Feb 26, 2024 going ex on Feb 09, 2024
Feb 12, 2024
Feb 26, 2024
Feb 09, 2024
Oct 31, 2023
TECH.NB Final Cash Dividend of gross USD 0.08 paid on Nov 24, 2023 going ex on Nov 09, 2023
Nov 10, 2023
Nov 24, 2023
Nov 09, 2023
Aug 08, 2023
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Sep 01, 2023 going ex on Aug 17, 2023
Aug 18, 2023
Sep 01, 2023
Aug 17, 2023
May 03, 2023
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on May 26, 2023 going ex on May 12, 2023
May 15, 2023
May 26, 2023
May 12, 2023
Feb 02, 2023
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Feb 27, 2023 going ex on Feb 10, 2023
Feb 13, 2023
Feb 27, 2023
Feb 10, 2023
Nov 01, 2022
TECH.NB Final Cash Dividend of gross USD 0.32 paid on Nov 28, 2022 going ex on Nov 10, 2022
Nov 14, 2022
Nov 28, 2022
Nov 10, 2022
Mehr Anzeigen
Aktien-Split
Datum
Art
Verhältnis
Nov 01, 2022
Split
1>4
Datum
Art
Verhältnis
Nov 01, 2022
Split
1>4